Molecular and Clinical Investigations on Portuguese Patients with Multiple acyl-CoA Dehydrogenase Deficiency

Author(s): Bárbara J. Henriques, Tânia G. Lucas, Esmeralda Martins, Ana Gaspar, Anabela Bandeira, Célia Nogueira, Otilia Brandão, Hugo Rocha, Laura Vilarinho*, Cláudio M. Gomes*.

Journal Name: Current Molecular Medicine

Volume 19 , Issue 7 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Background: Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) is a congenital rare metabolic disease with broad clinical phenotypes and variable evolution. This inborn error of metabolism is caused by mutations in the ETFA, ETFB or ETFDH genes, which encode for the mitochondrial ETF and ETF:QO proteins. A considerable group of patients has been described to respond positively to riboflavin oral supplementation, which constitutes the prototypic treatment for the pathology.

Objectives: To report mutations in ETFA, ETFB and ETFDH genes identified in Portuguese patients, correlating, whenever possible, biochemical and clinical outcomes with the effects of mutations on the structure and stability of the affected proteins, to better understand MADD pathogenesis at the molecular level.

Methods: MADD patients were identified based on the characteristic urinary profile of organic acids and/or acylcarnitine profiles in blood spots during newborn screening. Genotypic, clinical and biochemical data were collected for all patients. In silico structural analysis was employed using bioinformatic tools carried out in an ETF:QO molecular model for the identified missense mutations.

Results: A survey describing clinical and biochemical features of eight Portuguese MADD patients was made. Genotype analysis identified five ETFDH mutations, including one extension (p.X618QextX*14), two splice mutations (c.34+5G>C and c.405+3A>T) and two missense mutations (ETF:QO-p.Arg155Gly and ETF:QO-p.Pro534Leu), and one ETFB mutation (ETFβ- p.Arg191Cys). Homozygous patients containing the ETFDH mutations p.X618QextX*14, c.34+5G>C and ETF:QO-p.Arg155Gly, all presented severe (lethal) MADD phenotypes. However, when any of these mutations are in heterozygosity with the known ETF:QO-p.Pro534Leu mild variant, the severe clinical effects are partly and temporarily attenuated. Indeed, the latter destabilizes an ETF-interacting loop, with no major functional consequences. However, the position 155 in ETF:QO is localized at the ubiquinone binding and membrane interacting domain, and is thus expected to perturb protein structure and membrane insertion, with severe functional effects. Structural analysis of molecular models is therefore demonstrated to be a valuable tool to rationalize the effects of mutations in the context of the clinical phenotype severity.

Conclusion: Advanced molecular diagnosis, structural analysis and clinical correlations reveal that MADD patients harboring a severe prognosis mutation in one allele can actually revert to a milder phenotype by complementation with a milder mutation in the other allele. However, such patients are nevertheless in a precarious metabolic balance which can revert to severe fatal outcomes during catabolic stress or secondary pathology, thus requiring strict clinical follow-up.

Keywords: Glutaric aciduria type II, riboflavin responsive-MADD, structural biochemistry, rare disease, inborn error of metabolism, mitochondrial disease, newborn screening.

[1]
Frerman FE, Goodman SI, Scriver CR, et al. Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxidoreductase: Glutaric acidemia type ii the metabolic & molecular basis of inherited disease New York 2001; 2357-65.
[2]
Bosch AM, Abeling NG, Ijlst L, et al. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: A new inborn error of metabolism with potential treatment. J Inherit Metab Dis 2011; 34(1): 159-64.
[3]
Olsen RKJ, Koňaříková E, Giancaspero TA, et al. Riboflavin-Responsive and -Non-responsive Mutations in FAD Synthase Cause Multiple Acyl-CoA Dehydrogenase and Combined Respiratory-Chain Deficiency. Am J Hum Genet 2016; 98(6): 1130-45.
[4]
Missaglia S, Tavian D, Moro L, Angelini C. Characterization of two ETFDH mutations in a novel case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Lipids Health Dis 2018; 17(1): 254.
[5]
Loehr JP, Goodman SI, Frerman FE. Glutaric acidemia type II: heterogeneity of clinical and biochemical phenotypes. Pediatr Res 1990; 27(3): 311-5.
[6]
Antonacci R, Colombo I, Archidiacono N, et al. Assignment of the gene encoding the beta-subunit of the electron-transfer flavoprotein (ETFB) to human chromosome 19q13.3. Genomics 1994; 19(1): 177-9.
[7]
Barton DE, Yang-Feng TL, Finocchiaro G, Ozasa H, Tanaka K, Francke U. Short chain acyl-CoA dehydrogenase (ACADS) maps to chromosome 12 (q22-qter) and electron transfer flavoprotein (ETFA) to 15 (q23-q25). Cytogenet Cell Genet 1987; 46: 577-8.
[8]
Spector EB, Seltzer WK, Goodman SI. Assignment of electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO) to human chromosome 4q33 by fluorescence in situ hybridization and somatic cell hybridization. Mol Genet Metab 1999; 67(4): 364-7.
[9]
Olsen RK, Andresen BS, Christensen E, Bross P, Skovby F, Gregersen N. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum Mutat 2003; 22(1): 12-23.
[10]
Henriques BJ, Fisher MT, Bross P, Gomes CM. A polymorphic position in electron transfer flavoprotein modulates kinetic stability as evidenced by thermal stress. FEBS Lett 2011; 585(3): 505-10.
[11]
Henriques BJ, Rodrigues JV, Olsen RK, Bross P, Gomes CM. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. J Biol Chem 2009; 284(7): 4222-9.
[12]
Grünert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis 2014; 9: 117.
[13]
Henriques BJ, Lucas TG, Gomes CM. Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders. Curr Drug Targets 2016; 17(13): 1527-34.
[14]
Henriques BJ, Olsen RK, Bross P, Gomes CM. Emerging roles for riboflavin in functional rescue of mitochondrial β-oxidation flavoenzymes. Curr Med Chem 2010; 17(32): 3842-54.
[15]
Lucas TG, Henriques BJ, Rodrigues JV, Bross P, Gregersen N, Gomes CM. Cofactors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim Biophys Acta 2011; 1812(12): 1658-63.
[16]
Alves E, Henriques BJ, Rodrigues JV, et al. Mutations at the flavin binding site of ETF:QO yield a MADD-like severe phenotype in Drosophila. Biochim Biophys Acta 2012; 1822(8): 1284-92.
[17]
Gobin-Limballe S, McAndrew RP, Djouadi F, Kim JJ, Bastin J. Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches. Biochim Biophys Acta 2010; 1802(5): 478-84.
[18]
Henriques BJ, Bross P, Gomes CM. Mutational hotspots in electron transfer flavoprotein underlie defective folding and function in multiple acyl-CoA dehydrogenase deficiency. Biochim Biophys Acta 2010; 1802(11): 1070-7.
[19]
Zhang J, Frerman FE, Kim JJ. Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool. Proc Natl Acad Sci USA 2006; 103(44): 16212-7.
[20]
Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph 1990; 8(1): 52-6.
[21]
Laskowski RA, Chistyakov VV, Thornton JM. PDBsum more: new summaries and analyses of the known 3D structures of proteins and nucleic acids. Nucleic Acids Res 2005; 33: D266-8.
[22]
Yotsumoto Y, Hasegawa Y, Fukuda S, et al. Clinical and molecular investigations of Japanese cases of glutaric acidemia type 2. Mol Genet Metab 2008; 94(1): 61-7.
[23]
Wolfe LA, He M, Vockley J, et al. Novel ETF dehydrogenase mutations in a patient with mild glutaric aciduria type II and complex II-III deficiency in liver and muscle. J Inherit Metab Dis 2010; 33(Suppl. 3): S481-7.
[24]
Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008; 93(1): 36-9.
[25]
Pontoizeau C, Habarou F, Brassier A, et al. Hyperprolinemia in Type 2 Glutaric Aciduria and MADD-Like Profiles. JIMD Rep 2016; 27: 39-45.
[26]
Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban C. Electron transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet Metab 2006; 88(2): 153-8.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 7
Year: 2019
Page: [487 - 493]
Pages: 7
DOI: 10.2174/1566524019666190507114748
Price: $58

Article Metrics

PDF: 28
HTML: 7
PRC: 1